The Lancet. OncologyHumansEsophageal NeoplasmsMaleFemaleAntibodies
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial.
Jong-Mu Sun, Yee Chao, Sung-Bae Kim, Sun Young Rha, Thomas R Jeffry Evans, Andrew H Strickland, Zev Wainberg, Ian Chau, Sharon Pelles-Avraham, Jaffer Ajani, Ritu Malhotra, Qingyuan Liu, Sijing Li, Edward Cha, Melania Kalaitzidou
Published: 202610.1016/S1470-2045(25)00402-4
Abstract
BACKGROUND: Chemotherapy, with or without immunotherapy, is a standard of care for first-line treatment of locally advanced or metastatic oesophageal cancer. However, outcomes remain poor. We aimed to evaluate the activity and safety of tiragolumab,…
Preview only. Read the full abstract at the source